小豆蔻明调控自噬抑制卵巢癌SKOV3 细胞增殖的研究

目的：卵巢癌为女性常见病,死亡率高,分子靶向治疗药物较少,研发高效低毒的靶向新药意义重大。细胞自噬（autophagy） 维持着细胞内稳态和生长,是抗癌药物作用的关键靶部位。本课题旨在明确小豆蔻明（Cardamonin,CAR）调控自噬对卵巢癌 SKOV3 细胞增殖的影响。方法：体外培养卵巢癌SKOV3 细胞,不同药物分组处理,荧光显微镜下观察单黄酰戊二胺（MDC）染色 后细胞自噬囊泡,Western Blot 法检测细胞自噬相关蛋白LC3的表达,四氮唑蓝（MTT）法观察SKOV3 细胞增殖情况,流式细胞 术检测SKOV3 细胞凋亡的变化。结果：自噬抑制剂3-MA 显著性降低SKOV3 细胞内MDC染色的荧光颗粒数目、LC3Ⅱ蛋白表 达,抑制细胞增殖;而CAR（高、中剂量）、雷帕霉素和AZD8055 与3-MA 联用后细胞内MDC荧光颗粒数目增多、LC3Ⅱ蛋白表达 增加、细胞增殖抑制率及凋亡率明显升高;且高剂量CAR（10-5mol·L-1）的作用比低剂量CAR（10-6mol·L-1）明显。结论：CAR能够 抑制SKOV3 细胞增殖,诱导细胞自噬,促进细胞凋亡。CAR有望成为卵巢癌药物治疗的先导化合物。本研究为进一步研发此类 化合物提供了实验依据及一定的理论基础。     

白花蛇舌草多糖提取物对喉癌Hep-2细胞内质网自噬的影响*

目的:探讨白花蛇舌草多糖提取物(HDPE)对喉癌Hep-2细胞内质网自噬的影响。方法:实验分为对照组、HDPE 100、200、400 mg/L组和3-MA(自噬抑制剂)组,噻唑盐比色法(MTT)检测各组细胞培养24 h、48 h、72 h后增殖抑制率;原位末端转移酶标记法(TUNEL)法检测各组培养48 h细胞凋亡情况;单丹黄酰尸胺(MDC)染色观察各组培养48 h细胞自噬体及自噬溶酶体的变化;透射电镜观察培养48 h细胞内质网周围自噬囊泡的产生情况;蛋白印迹法(Western blot)检测各组培养48 h细胞Beclin-1蛋白(Beclin-1)、微管相关轻链蛋白3Ⅰ(LC3Ⅰ)、微管相关轻链蛋白3Ⅱ(LC3Ⅱ)、葡萄糖调节蛋白 78(GRP78)、活化转录因子6(ATF6)及CCAAT 增强子结合蛋白同源蛋白(CHOP)表达。结果:与对照组比较,HDPE 100、200、400 mg/L组和3-MA组细胞增殖抑制率、凋亡指数AI升高,MDC阳性细胞率量降低,内质网周围自噬囊泡减少,GRP78、ATF6及CHOP表达及LC3Ⅰ/LC3Ⅱ比值升高,Beclin-1表达降低(P＜0.05);与3-MA组比较,HDPE 400 mg/L组细胞增殖抑制率、凋亡指数AI升高,MDC阳性细胞率、GRP78、ATF6及CHOP表达及LC3Ⅰ/LC3Ⅱ比值升高,Beclin-1表达降低(P＜0.05)。结论:HDPE可能通过抑制喉癌Hep-2细胞内质网自噬,促进细胞内质网应激凋亡,进而抑制Hep-2细胞增殖能力。     

自噬抑制剂3-MA上调H2O2损伤的PC12细胞氧化应激水平

为探究自噬抑制剂6-氨基-3-甲基腺嘌呤（3-methyladenine,3-MA）对损伤细胞氧化应激水平的影响,将3-MA作用于H2O2诱导的PC12细胞损伤模型,以自噬增强剂雷帕霉素（rapamycin,Rap）作为对照,探讨自噬与氧化应激的关系。测定线粒体的膜电位和细胞内的活性氧（reactive oxygen species, ROS）与丙二醛(malondialdehyde, MDA)含量,以及超氧化物歧化酶(superoxide dismutase,SOD)和过氧化氢酶(catalase,CAT)活性,评价损伤细胞的氧化应激状态。单丹(磺)酰戊二胺（monodansylcadaverine,MDC）染色,观察损伤细胞的自噬情况。蛋白质印迹分析损伤细胞中的自噬相关蛋白质LC3-II/LC3-I比值变化。实验结果显示：与正常组相比,H2O2损伤细胞的ROS水平上升到正常组的141%,MDA含量增加(P<0.001);CAT与SOD酶活力显著降低(P<0.001),差异均有统计学意义,证明损伤细胞氧化应激水平增加;MDC染色结果表明,H2O2组自噬明显增加。Western印迹结果表明,LC3-II/LC3-I值显著升高（P<0.05）;与损伤组相比,3-MA组MDC染色结果表明,自噬水平降低。Western印迹结果表明,LC3-II/LC3-I值下降;细胞内ROS水平升高,增加到正常组的208%。MDA含量增加(P<0.001),CAT、SOD酶活力降低(P<0.001)。综上结果表明,自噬抑制剂可增加H2O2诱导的PC12细胞损伤模型的氧化应激水平,增加细胞凋亡。     

自噬抑制剂氯奎对低氧诱导肺动脉平滑肌细胞增殖的影响

目的：探讨自噬抑制刺氯喹（cQ）在低氧（hypoxia）调节肺动脉平滑肌细胞（PASMCs）增殖中的作用。方法：将体外培养的大鼠PASMCs分为4组：正常对照组、1％低氧组、50μmol／L氯喹＋1％低氧组、50ttmol／L氯喹组。MTF方法检测各组的PASMCs增殖率;MDC染色检测细胞自噬空泡的变化;Westernblot方法检测微管相关蛋白轻链3（LC3）蛋白的表达变化;划痕法检测细胞迁移的变化。结果：与对照组比较,氯喹组的PASMCs细胞增殖率无明显变化。与对照组比较,1％低氧组PASMCs增殖率明显增加,细胞内出现大量自噬空泡,细胞迁移速度明显增加。细胞LC3-Ⅱ蛋白表达增强。与1％低氧组比较,氯喹与低氧联合作用时细胞自噬空泡的积聚以及rE3．II蛋白表达增强,但细胞增殖率和迁移明显降低。结论：低氧激活自噬过程并促进了PASMCs增殖和迁移,而自噬抑制剂氯喹在一定程度上通过抑制自噬进程,达到抑制肺动脉平滑肌细胞增殖和迁移的作用。     

自噬在TXNIP过表达诱导的INS-1胰岛细胞凋亡中的作用

硫氧还蛋白相互作用蛋白(thioredoxin interacting protein,TXNIP)是内源性硫氧还蛋白结合抑制蛋白,在糖尿病患者血清和组织中均高表达。本研究观察TXNIP过表达对正常糖脂浓度下培养的INS-1细胞自噬水平的影响,并分析自噬在TXNIP诱导的细胞凋亡中的作用。常规培养的INS-1胰岛细胞分为正常培养组、空病毒(Ad-eGFP)组和TXNIP过表达(Ad-TXNIP-eGFP)组,后两组转染相应腺病毒,48 h后测定TXNIP mRNA和蛋白的表达情况;用Western blot检测各组自噬相关的Beclin-1、LC3和P62的蛋白表达情况,以cleaved caspase 3/caspase 3比值和流式细胞术检测各组细胞凋亡情况;用IF/ICC法检测各组细胞内自噬体数量的变化。结果显示,与Ad-eGFP组相比,Ad-TXNIP-eGFP组TXNIP mRNA和蛋白表达量均明显升高;与Ad-eGFP组相比,Ad-TXNIP-eGFP组LC3-II/LC3-I比值和Beclin-1蛋白表达水平升高,P62蛋白表达降低,自噬体荧光强度增强,细胞凋亡率升高,cleaved caspase 3/caspase 3比值上升。使用自噬抑制剂3-MA干预后,与TXNIP过表达组相比,TXNIP过表达+3-MA组自噬明显受到抑制,同时凋亡明显减轻。以上结果提示,在正常糖脂浓度培养下的INS-1细胞过表达TXNIP可以通过诱导自噬促进细胞凋亡。     

Sfrp1通过阻断Wnt信号通路减轻血管紧张素Ⅱ诱导的心脏损伤并促进自噬的研究

摘要 目的：本研究旨在评估Sfrp1在血管紧张素II诱导的心肌肥厚中的心脏保护作用，并探讨其与自噬和Wnt信号通路相关的可能机制。方法：利用重组AAV9载体将Sfrp1导入Ang II诱导的肥厚型H9C2心肌细胞。用CCK8测定细胞活力。流式细胞仪检测细胞凋亡率。用显微照片记录肥厚细胞大小的变化。western blot检测Sfrp1、Bcl-2、Bax、CytC、Caspase-3、P62、ATG5、Beclin、LC3、β-catenin和DVL1的蛋白表达。通过qRT-PCR检测β-连环蛋白和DVL1的mRNA表达。自噬抑制剂3-MA也用于验证治疗过程中自噬的参与。结果：（1）Sfrp1成功转染H9C2细胞，其过度表达减轻了心肌肥厚。（2）经过AAV9-Sfrp1预处理可减少肥厚心肌的细胞凋亡，可逆转Ang II组自噬相关蛋白（p62、ATG5、Beclin、LC3）的表达；（3）自噬在治疗心肌肥厚过程中的作用通过可自噬抑制剂3-MA来证实。（4）激活的Wnt信号（β-连环蛋白，DVL1）也被AAV9-Sfrp1抑制。结论：Sfrp1通过Wnt信号通路促进细胞自噬，从而保护心肌细胞免受肥厚性损伤和凋亡，这为Sfrp1对心肌肥厚的心肌保护作用机制提供了一个重要的视角。     

细胞自噬对酒精诱导的肝细胞毒性的保护作用

目的：研究细胞自噬对酒精诱导的人肝细胞系（CL-1）的保护作用。方法：培养正常肝细胞系CL-1细胞,80mmol／L酒精常规处理24小时,采用CCK-8法观察酒精对细胞活力的影响;流式细胞技术观察酒精对细胞凋亡的影响;免疫蛋白印迹及转染GFP-LC3法检测细胞自噬水平;选用rapamycin和3-MA调节细胞自噬,观察酒精处理后细胞活力及凋亡的变化。结果：酒精处理体外培养的CL-1细胞,实验组较对照组细胞活力下降（P〈0．05）;实验组细胞46．2％发生凋亡,显著高于对照组8．4％;LC3II及Beclinl水平显著高于对照组;GFP-LC3荧光数显著高于对照组（P〈0．05）;调节细胞自噬水平,rapamycin组细胞活性增加（P〈0．01）,31．1％（46．2％）细胞发生凋亡;3-MA组细胞活性降低（P〈0．05）,54．1％（46．2％）细胞发生凋亡。结论：酒精处理降低CL-1细胞活性,促进凋亡,提高自噬水平;提高或降低细胞自噬水平,细胞凋亡及活力随之降低和增加;细胞自噬能够对抗酒精诱导的肝细胞凋亡。     

抑制自噬促进冬凌草甲素诱导的多发性骨髓瘤细胞凋亡涉及胞内ROS产生

目的本实验主要研究冬凌草甲素诱导多发性骨髓瘤发生自噬、凋亡,两者之间的关系以及所涉及的相关机制。方法利用MTT比色法检测冬凌草甲素对多发性骨髓瘤RPMI8226细胞的增殖活性影响;透视电镜观察细胞内凋亡和自噬的形态学改变;TUNEL检测细胞凋亡;分别利用以下技术检测处理后的细胞内的自噬变化:使用QDs605nm-Anti-LC3荧光探针以及免疫荧光技术定位细胞胞内LC3Ⅰ和LC3Ⅱ蛋白,利用western blot免疫印记技术检测Beclin 1蛋白表达水平;利用DCFH-DA探针以及流式细胞术检测细胞胞内ROS水平。结果冬凌草甲素能明显抑制RPMI8226细胞增殖,其抑制作用呈时间、剂量依赖性;冬凌草甲素能同时诱发细胞凋亡、自噬和胞内ROS产生;NAC完全抑制胞内ROS产生后冬凌草甲素诱导的细胞凋亡消失;3-MA抑制自噬后,冬凌草甲素诱导的胞内ROS产生进一步增多,凋亡增多。结论冬凌草甲素能明显抑制RPMI8226细胞增殖;冬凌草甲素同时诱发细胞凋亡和自噬;胞内ROS产生介导冬凌草甲素诱导的凋亡;凋亡为细胞死亡的主要途径,而自噬通过下调胞内ROS产生抑制凋亡。     

过表达TRAF6对人急性髓系白血病细胞自噬活性的影响

该文旨在探讨过表达肿瘤坏死因子受体相关因子6(tumor necrosis factor receptorassociated factor 6,TRAF6)对人急性髓系白血病(acute myeloid leukemia,AML)细胞自噬活性的影响。利用基因表达数据库GEO分析TRAF6在AML患者白血病细胞中的mRNA表达水平。通过癌症基因组图谱TCGA分析TRAF6表达与AML患者临床预后的关系。将TRAF6重组质粒载体转染人AML细胞系(KG-1a和THP-1),采用自噬激活剂雷帕霉素(Rapamycin)和自噬相关抑制剂3-甲基腺嘌呤(3-methyladenine,3-MA)、巴弗洛霉素A1(bafilomycin A1,Baf-A1)分别处理AML细胞。荧光定量PCR、蛋白免疫印迹技术检测过表达TRAF6后白血病细胞自噬标志物(LC3和p62)mRNA和蛋白水平;免疫荧光方法检测LC3绿色荧光斑点结构(puncta);流式细胞术检测细胞凋亡率;CCK-8实验检测AML细胞的体外增殖能力。结果显示,AML患者白血病细胞高表达TRAF6(P<0.01);TRAF6高表达的白血病患者总体生存率和无事件生存率均较TRAF6低表达组显著降低(P=0.01)。TRAF6重组质粒转染能够显著增加两株AML细胞系中TRAF6的mRNA和蛋白水平(P<0.05)。Rapamycin处理能够激活AML细胞系自噬水平,过表达TRAF6后AML细胞LC3 mRNA和LC3II蛋白水平表达上调(P<0.05)、p62 mRNA和蛋白水平下调(P<0.05)以及LC3 puncta聚集增多。用Baf-A1处理以阻断过表达TRAF6的白血病细胞系中的自噬流后,LC3II蛋白表达水平显著提高(P<0.05)。3-MA处理过表达TRAF6的白血病细胞后,LC3II蛋白表达减少、p62蛋白表达增加(P<0.05)。此外,过表达TRAF6降低白血病细胞凋亡率和促进细胞的体外增殖(P<0.001),而过表达TRAF6后联合3-MA处理则可逆转TRAF6对白血病细胞的抗凋亡和促增殖作用(P<0.001)。以上研究结果提示,过表达TRAF6能够增强AML细胞的自噬活性,促进AML细胞的生长。     

Bel-7402细胞通过自噬逃避FAS/ActD诱导的凋亡

为了探究FAS抗体与放线菌素D（actinomycin D,ActD）诱导肝癌细胞Bel-7402凋亡的作用机制,通过自噬阻断剂3-MA的作用,来探讨自噬与凋亡的关系.利用电子显微镜和流式细胞仪观察细胞自噬及凋亡.结果表明,FAS/ActD在诱导细胞凋亡的同时伴有细胞自噬现象,在3-MA作用下,FAS/ActD所诱导的细胞自噬体减少,而凋亡现象严重.并且通过流式细胞仪分析表明,3-MA明显增高FAS/ActD所诱导的细胞凋亡率. Western印迹分析进一步显示,FAS/ActD能引起caspase-3激活产生断裂,同时刺激LC3和BECN1表达,而3-MA作用后自噬体减少,同时LC3和BECN1表达降低,但是caspase-3断裂带表达明显增加.以上结果提示,FAS/ActD诱导的Bel-7402细胞凋亡的同时伴有细胞自噬,Bel-7402细胞通过自噬逃避FAS/ActD诱导的凋亡.     

Crosstalk between autophagy and apoptosis in the regulation of paclitaxel-induced cell death in v-Ha-ras-transformed fibroblasts

The previous studies by this author group has shown that paclitaxel, a mitotic inhibitor used in breast cancer chemotherapy, inhibits cell growth via induction of Raf-1-dependent apoptosis. In this article, the role of autophagy in paclitaxel anticancer action was investigated using v-Ha-ras-transformed NIH 3T3 cells. Paclitaxel induced a notable increase in the number of fluorescent particles labeled with monodansylcadaverine (MDC), a specific marker for autophagic vacuoles. MDC-labeled vacuoles clearly exhibited the fluorescent-tagged LC3 in cells transiently overexpressing GFP-LC3 (a protein that associates with autophagosome membranes). However, autophagy inhibition with 3-methyladenine (3-MA) failed to rescue v-Ha-ras-transformed NIH 3T3 cells from paclitaxel-induced cell death. More interestingly, the apoptosis inhibition by overexpression of the X-linked inhibitor of apoptosis (XIAP) did not fully block the cell death by paclitaxel, implying that apoptosis inhibition might accelerate the autophagic components of the paclitaxel response. Conversely, Raf-1 shRNA expression protected against paclitaxel-induced cell death through the simultaneous inhibition of both autophagy and apoptosis. These results suggest that both autophagy and apoptosis act as cooperative partners to induce cell death in v-Ha-ras-transformed NIH 3T3 cells treated with paclitaxel.     

Mimulone-Induced Autophagy through p53-Mediated AMPK/mTOR Pathway Increases Caspase-Mediated Apoptotic Cell Death in A549 Human Lung Cancer Cells

Anticancer properties and mechanisms of mimulone (MML), C-geranylflavonoid isolated from the Paulownia tomentosa fruits, were firstly elucidated in this study. MML prevented cell proliferation in a dose- and time-dependent way and triggered apoptosis through the extrinsic pathway in A549 human lung adenocarcinoma cells. Furthermore, MML-treated cells displayed autophagic features, such as the formation of autophagic vacuoles, a primary morphological feature of autophagy, and the accumulation of microtubule-associated protein 1 light chain 3 (LC3) puncta, another typical maker of autophagy, as determined by FITC-conjugated immunostaining and monodansylcadaverine (MDC) staining, respectively. The expression levels of LC3-I and LC3-II, specific markers of autophagy, were also augmented by MML treatment. Autophagy inhibition by 3-methyladenine (3-MA), pharmacological autophagy inhibitor, and shRNA knockdown of Beclin-1 reduced apoptotic cell death induced by MML. Autophagic flux was not significantly affected by MML treatment and lysosomal inhibitor, chloroquine (CQ) suppressed MML-induced autophagy and apoptosis. MML-induced autophagy was promoted by decreases in p53 and p-mTOR levels and increase of p-AMPK. Moreover, inhibition of p53 transactivation by pifithrin-α (PFT-α) and knockdown of p53 enhanced induction of autophagy and finally promoted apoptotic cell death. Overall, the results demonstrate that autophagy contributes to the cytotoxicity of MML in cancer cells harboring wild-type p53. This study strongly suggests that MML is a potential candidate for an anticancer agent targeting both autophagy and apoptotic cell death in human lung cancer. Moreover, co-treatment of MML and p53 inhibitor would be more effective in human lung cancer therapy.     

Dendropanoxide Induces Autophagy through ERK1/2 Activation in MG-63 Human Osteosarcoma Cells and Autophagy Inhibition Enhances Dendropanoxide-Induced Apoptosis

Anticancer effects of dendropanoxide (DP) newly isolated from leaves and stem of Dendropanax morbifera Leveille were firstly investigated in this study. DP inhibited cell proliferation and induced apoptosis in dose- and time-dependent manner in MG-63 human osteosarcoma cells, which was dependent on the release of cytochrome c to the cytosol and the activation of caspases. Moreover, the DP-treated cells exhibited autophagy, as characterized by the punctuate patterns of microtubule-associated protein 1 light chain 3 (LC3) by confocal microscopy and the appearance of autophagic vacuoles by MDC staining. The expression levels of ATG7, Beclin-1 and LC3-II were also increased by DP treatment. Inhibition of autophagy by 3-methyladenine (3-MA) and wortmannin (Wort) significantly enhanced DP-induced apoptosis. DP treatment also caused a time-dependent increase in protein levels of extracellular signal-regulated kinase 1 and 2 (ERK1/2), and inhibition of ERK1/2 phosphorylation with U0126 resulted in a decreased DP-induced autophagy that was accompanied by an increased apoptosis and a decreased cell viability. These results indicate a cytoprotective function of autophagy against DP-induced apoptosis and suggest that the combination of DP treatment with autophagy inhibition may be a promising strategy for human osteosarcoma control. Taken together, this study demonstrated for the first time that DP could induce autophagy through ERK1/2 activation in human osteosarcoma cells and autophagy inhibition enhanced DP-induced apoptosis.     

Novel monofunctional platinum (II) complex Mono-Pt induces apoptosis-independent autophagic cell death in human ovarian carcinoma cells,distinct from cisplatin

Failure to engage apoptosis appears to be a leading mechanism of resistance to traditional platinum drugs in patients with ovarian cancer. Therefore, an alternative strategy to induce cell death is needed for the chemotherapy of this apoptosis-resistant cancer. Here we report that autophagic cell death, distinct from cisplatin-induced apoptosis, is triggered by a novel monofunctional platinum (II) complex named Mono-Pt in human ovarian carcinoma cells. Mono-Pt-induced cell death has the following features: cytoplasmic vacuolation, caspase-independent, no nuclear fragmentation or chromatin condensation, and no apoptotic bodies. These characteristics integrally indicated that Mono-Pt, rather than cisplatin, initiated a nonapoptotic cell death in Caov-3 ovarian carcinoma cells. Furthermore, incubation of the cells with Mono-Pt but not with cisplatin produced an increasing punctate distribution of microtubule-associated protein 1 light chain 3 (LC3), and an increasing ratio of LC3-II to LC3-I. Mono-Pt also caused the formation of autophagic vacuoles as revealed by monodansylcadaverine staining and transmission electron microscopy. In addition, Mono-Pt-induced cell death was significantly inhibited by the knockdown of either BECN1 or ATG7 gene expression, or by autophagy inhibitors 3-methyladenine, chloroquine and bafilomycin A₁. Moreover, the effect of Mono-Pt involved the AKT1-MTOR-RPS6KB1 pathway and MAPK1 (ERK2)/MAPK3 (ERK1) signaling, since the MTOR inhibitor rapamycin increased, while the MAPK1/3 inhibitor U0126 decreased Mono-Pt-induced autophagic cell death. Taken together, our results suggest that Mono-Pt exerts anticancer effect via autophagic cell death in apoptosis-resistant ovarian cancer. These findings lead to increased options for anticancer platinum drugs to induce cell death in cancer.     

Induction of autophagic cell death in human ovarian carcinoma cells by Antrodia salmonea through increased reactive oxygen species generation

We reported in our previously executed studies that the fermented culture broth of Antrodia salmonea (AS), a mushroom used in Taiwanese folk medicine induced reactive oxygen species (ROS)-mediated apoptosis in human ovarian carcinoma cells. In this study, we studied the anticancer efficacies of AS (0–240 μg/ml) by examining the key molecular events implicated in cell death associated with autophagy in SKOV-3 and A2780 human ovarian carcinoma cells and clarified the fundamental molecular mechanisms. Treatment of ovarian carcinoma cells with AS-induced autophagic cell death mediated by increased microtubule-associated protein LC3-II, GFP-LC3 puncta, and acidic vesicular organelle (AVO) formation. These events are linked with the activation of p62/SQSTM1, the inhibition of ATG4B, the expression of ATG7, and the dysregulation of Beclin-1/Bcl-2 (i.e., B-cell lymphoma 2). N-acetylcysteine inhibited AS-induced ROS generation, which in turn constricted AS-induced LC3 conversion, AVO formation, and ATG4B inhibition, indicating ROS-mediated autophagy cell death. In addition, the 3-methyladenine (3-MA) or chloroquine (CQ)-induced autophagy inhibition decreased AS-induced apoptosis. Additionally, apoptosis inhibition by Z-VAD-FMK, a pan-caspase inhibitor, substantially suppressed AS-induced autophagy. Furthermore, AS-inhibited HER-2/ neu and PI3K/AKT signaling pathways which were reversed by autophagy inhibitors 3-MA and CQ. Thus, A. salmonea is a potential chemopreventive agent that is capable of activating ROS-mediated autophagic cell death in ovarian carcinoma cells.     

The role of autophagy in human endometrium

Autophagy appears to play an important role in the normal development and maintenance of homeostasis in a variety of tissues, including the female reproductive tract. However, the role of autophagy and the association between autophagy and apoptosis in cyclic remodeling of the human endometrium have not been described. Therefore, we investigated the involvement of autophagy during the human endometrial cycle and its association with apoptosis. Endometrial samples were obtained from 15 premenopausal, nonpregnant women who underwent hysterectomies for benign gynecological reasons. The autophagy-associated protein, microtubule-associated protein 1 light chain 3 alpha (MAP1LC3A), was immunolocalized, and its expression level was measured by Western blot analysis. Apoptosis was evaluated by measuring the expression level of cleaved caspase 3 protein. MAP1LC3A protein was primarily expressed within the endometrial glandular cells and increased during the secretory phase. The expression level of the membrane-bound form of MAP1LC3A (MAP1LC3A-II) also increased as the menstrual cycle progressed, reaching a maximum level during the late secretory phase. This pattern coincided with the expression of cleaved caspase 3. Furthermore, expression of MAP1LC3A-II and cleaved caspase 3 increased in the in vitro-cultured endometrial cancer cells when estrogen and/or progesterone were withdrawn from the culture media to mimic physiological hormonal changes. These findings suggest that endometrial cell autophagy is directly involved in the cyclic remodeling of the human endometrium and is correlated with apoptosis. In addition, we inhibited autophagic processes using 3-methyladenine (3-MA) or bafilomycin A1 (Baf A1) to evaluate the role of autophagy in apoptosis induction in endometrial cancer cells. While the inhibition of autophagosome formation using 3-MA did not decrease apoptosis or cell death, the inhibition of autophagosome degradation by fusion with lysosomes using Baf A1 increased apoptosis and cell death, suggesting that the accumulation of autophagosomes induces apoptosis. Furthermore, Baf A1-induced apoptotic cell death was decreased by the apoptosis inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (Z-VAD-FMK). In conclusion, these results indicate that autophagy is involved in the endometrial cell cycle affecting apoptosis and is most prominent during the late secretory phase.     

4th International Symposium on Autophagy: Exploiting the Frontiers of Autophagy Research

Minocycline has been shown to alleviate several neurological disorders. Unexpectedly, we found that minocycline had opposite effects on glioma cells: minocycline induced nonapoptotic cell death in glioma cells. The glioma cell death was associated with the presence of autophagic vacuoles in the cytoplasm. Minocycline induced autophagy was confirmed by acridine orange, monodansylcadaverine (MDC) stainings of vesicle formation and the conversion of microtubule-associated proteins light chain 3 (LC3-I) to LC3-II. Pretreatment with autophagy inhibitor 3-methyladenine (3-MA) suppressed the induction of acidic vesicular organelles and the accumulation of LC3-II to the autophagosome membrane in glioma cells treated with minocycline. Despite the pretreatment of 3-MA, minocycline induced cell death which could result from the activation of caspase-3. Minocycline effectively inhibited tumor growth and induced autophagy in the xenograft tumor model of C6 glioma cells. These results suggest that minocycline may kill glioma cells by inducing autophagic cell death. When autophagy was inhibited, minocycline still induced cell death through the activation of caspase-3. Thus, minocycline is a promising agent in the treatment of malignant gliomas.